Robinson Elliott sold 0 shares of HNGE (indirect holdings)

Hinge Health (HNGE) filed a notice under Rule 144 for potential sales of Class A shares by the Jeffrey Lieberman 2012 Family Trust, a 10% stockholder. Recent sales by Insight Venture Partners funds included blocks of shares totaling millions. Raymond James & Associates is the broker. HNGE has 62.47 million Class A shares outstanding.

Hinge Health (NYSE:HNGE) raised its 2026 revenue guidance to $856M-$860M, up from $822.16M consensus. Q2 2026 revenue grew 53% YoY to $213M, with non-GAAP operating income doubling to $62M. The company announced a $105M acquisition of Cylinder Health and expanded its share repurchase program by $300M. Analysts RBC and Truist raised price targets to $110 and $112, respectively, citing strong growth and platform expansion.

Hinge Health (HNGE) stock has risen 90% YTD, outperforming industry and S&P 500. Q2 revenue grew 53% YoY to $213M, with 2026 guidance raised to $856-$860M. AI and automation improved margins, while new care programs expand market reach. Analysts project 2026 EPS of $2.50 and 2027 EPS of $3.29. Growth is driven by member yield, AI efficiency, and new care offerings, but execution risks remain.

Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.

Hinge Health (NASDAQ:HNGE) reported Q2 revenue of $213 million, up 53% year over year, above guidance of $200 million to $202 million. Gross margin rose to 87% and operating income to $62 million. The company said it used $105 million cash to acquire Cylinder Health for gastrointestinal care, while also expanding its migraine offering. It raised FY revenue guidance to $856 million to $860 million and authorized a $300 million buyback.

Hinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.